Loading…
Estimating the Value of a Generic Quality-of-Life Measure
In this paper, data from a clinical trial of a new antiviral agent for treating patients with zoster are used to answer the following question: Does the Nottingham Health Profile (NHP) add to the information obtained from the clinical measures? Three ways in which the NHP could add information are m...
Saved in:
Published in: | Medical care 1995-04, Vol.33 (4), p.AS195-AS202 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | AS202 |
container_issue | 4 |
container_start_page | AS195 |
container_title | Medical care |
container_volume | 33 |
creator | Mauskopf, Josephine A. Austin, Randall Dix, Lynn P. Berzon, Richard A. |
description | In this paper, data from a clinical trial of a new antiviral agent for treating patients with zoster are used to answer the following question: Does the Nottingham Health Profile (NHP) add to the information obtained from the clinical measures? Three ways in which the NHP could add information are measured. First, Cox's regression analysis is used to determine whether health-related quality-of-life scores obtained at diagnosis give information about disease prognosis. Second, changes in mean NHP scores in different dimensions are computed after pain resolution to determine whether NHP scores provide more sensitive indicators of disease resolution. Third, linear regression is used to determine whether the impacts of disease on quality of life are measured adequately by the clinical parameters. These analyses show that use of the physical mobility and energy dimensions of the NHP increases understanding of disease prognosis; demonstrates the continuing impact of zoster on patients' sleep patterns and energy levels, disease symptoms not included as clinical measures, that persist after the cessation of zoster-associated pain; and gives a measure of the impact of zoster on the patient, which includes unmeasured and measured levels of severity. |
format | article |
fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_77223874</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>3766626</jstor_id><sourcerecordid>3766626</sourcerecordid><originalsourceid>FETCH-LOGICAL-j229t-1eee72927fa6549b2395140dd5760163bb45ed3a28e7a9d4a37d5044d7c942eb3</originalsourceid><addsrcrecordid>eNo9j81KxDAYRbNQxnH0DRSychdI8_dNljKMo1ARQd2WtPmqKf0Zm3Qxb29hiqu7OIcL54KsOReaAQd7Ra5jbDjPQGqxIisAIZWCNbH7mELnUui_afpB-uXaCelQU0cP2OMYKvo-uTakExtqloca6Su6OI14Qy5r10a8XXZDPp_2H7tnlr8dXnaPOWuEsIlliAjCCqid0cqWQlqdKe69BsMzI8tSafTSiS2Cs145CV5zpTxUVgks5YY8nH-P4_A7YUxFF2KFbet6HKZYzClCbkHN4v0iTmWHvjiOc9h4KpbWmd-deRPTMP5jCcYYYeQfdnNWoA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77223874</pqid></control><display><type>article</type><title>Estimating the Value of a Generic Quality-of-Life Measure</title><source>JSTOR Archival Journals and Primary Sources Collection</source><creator>Mauskopf, Josephine A. ; Austin, Randall ; Dix, Lynn P. ; Berzon, Richard A.</creator><creatorcontrib>Mauskopf, Josephine A. ; Austin, Randall ; Dix, Lynn P. ; Berzon, Richard A.</creatorcontrib><description>In this paper, data from a clinical trial of a new antiviral agent for treating patients with zoster are used to answer the following question: Does the Nottingham Health Profile (NHP) add to the information obtained from the clinical measures? Three ways in which the NHP could add information are measured. First, Cox's regression analysis is used to determine whether health-related quality-of-life scores obtained at diagnosis give information about disease prognosis. Second, changes in mean NHP scores in different dimensions are computed after pain resolution to determine whether NHP scores provide more sensitive indicators of disease resolution. Third, linear regression is used to determine whether the impacts of disease on quality of life are measured adequately by the clinical parameters. These analyses show that use of the physical mobility and energy dimensions of the NHP increases understanding of disease prognosis; demonstrates the continuing impact of zoster on patients' sleep patterns and energy levels, disease symptoms not included as clinical measures, that persist after the cessation of zoster-associated pain; and gives a measure of the impact of zoster on the patient, which includes unmeasured and measured levels of severity.</description><identifier>ISSN: 0025-7079</identifier><identifier>PMID: 7723447</identifier><language>eng</language><publisher>United States: J. B. Lippincott Co</publisher><subject>Acyclovir - analogs & derivatives ; Acyclovir - therapeutic use ; Antiviral Agents - therapeutic use ; Central nervous system viral diseases ; Choosing Questions ; Clinical trials ; Demography ; Diabetes ; Double-Blind Method ; Exanthema ; Female ; Herpes zoster ; Herpes Zoster - drug therapy ; Herpes Zoster - psychology ; Humans ; Male ; Middle Aged ; Nervous system diseases ; Outcome Assessment (Health Care) ; Pain ; Pain - psychology ; Prognosis ; Quality of Life ; Regression Analysis ; Sleep ; Symptoms ; Valine - analogs & derivatives ; Valine - therapeutic use</subject><ispartof>Medical care, 1995-04, Vol.33 (4), p.AS195-AS202</ispartof><rights>Copyright 1995 J. B. Lippincott Company</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/3766626$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/3766626$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,58238,58471</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7723447$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mauskopf, Josephine A.</creatorcontrib><creatorcontrib>Austin, Randall</creatorcontrib><creatorcontrib>Dix, Lynn P.</creatorcontrib><creatorcontrib>Berzon, Richard A.</creatorcontrib><title>Estimating the Value of a Generic Quality-of-Life Measure</title><title>Medical care</title><addtitle>Med Care</addtitle><description>In this paper, data from a clinical trial of a new antiviral agent for treating patients with zoster are used to answer the following question: Does the Nottingham Health Profile (NHP) add to the information obtained from the clinical measures? Three ways in which the NHP could add information are measured. First, Cox's regression analysis is used to determine whether health-related quality-of-life scores obtained at diagnosis give information about disease prognosis. Second, changes in mean NHP scores in different dimensions are computed after pain resolution to determine whether NHP scores provide more sensitive indicators of disease resolution. Third, linear regression is used to determine whether the impacts of disease on quality of life are measured adequately by the clinical parameters. These analyses show that use of the physical mobility and energy dimensions of the NHP increases understanding of disease prognosis; demonstrates the continuing impact of zoster on patients' sleep patterns and energy levels, disease symptoms not included as clinical measures, that persist after the cessation of zoster-associated pain; and gives a measure of the impact of zoster on the patient, which includes unmeasured and measured levels of severity.</description><subject>Acyclovir - analogs & derivatives</subject><subject>Acyclovir - therapeutic use</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Central nervous system viral diseases</subject><subject>Choosing Questions</subject><subject>Clinical trials</subject><subject>Demography</subject><subject>Diabetes</subject><subject>Double-Blind Method</subject><subject>Exanthema</subject><subject>Female</subject><subject>Herpes zoster</subject><subject>Herpes Zoster - drug therapy</subject><subject>Herpes Zoster - psychology</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nervous system diseases</subject><subject>Outcome Assessment (Health Care)</subject><subject>Pain</subject><subject>Pain - psychology</subject><subject>Prognosis</subject><subject>Quality of Life</subject><subject>Regression Analysis</subject><subject>Sleep</subject><subject>Symptoms</subject><subject>Valine - analogs & derivatives</subject><subject>Valine - therapeutic use</subject><issn>0025-7079</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><recordid>eNo9j81KxDAYRbNQxnH0DRSychdI8_dNljKMo1ARQd2WtPmqKf0Zm3Qxb29hiqu7OIcL54KsOReaAQd7Ra5jbDjPQGqxIisAIZWCNbH7mELnUui_afpB-uXaCelQU0cP2OMYKvo-uTakExtqloca6Su6OI14Qy5r10a8XXZDPp_2H7tnlr8dXnaPOWuEsIlliAjCCqid0cqWQlqdKe69BsMzI8tSafTSiS2Cs145CV5zpTxUVgks5YY8nH-P4_A7YUxFF2KFbet6HKZYzClCbkHN4v0iTmWHvjiOc9h4KpbWmd-deRPTMP5jCcYYYeQfdnNWoA</recordid><startdate>19950401</startdate><enddate>19950401</enddate><creator>Mauskopf, Josephine A.</creator><creator>Austin, Randall</creator><creator>Dix, Lynn P.</creator><creator>Berzon, Richard A.</creator><general>J. B. Lippincott Co</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19950401</creationdate><title>Estimating the Value of a Generic Quality-of-Life Measure</title><author>Mauskopf, Josephine A. ; Austin, Randall ; Dix, Lynn P. ; Berzon, Richard A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j229t-1eee72927fa6549b2395140dd5760163bb45ed3a28e7a9d4a37d5044d7c942eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Acyclovir - analogs & derivatives</topic><topic>Acyclovir - therapeutic use</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Central nervous system viral diseases</topic><topic>Choosing Questions</topic><topic>Clinical trials</topic><topic>Demography</topic><topic>Diabetes</topic><topic>Double-Blind Method</topic><topic>Exanthema</topic><topic>Female</topic><topic>Herpes zoster</topic><topic>Herpes Zoster - drug therapy</topic><topic>Herpes Zoster - psychology</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nervous system diseases</topic><topic>Outcome Assessment (Health Care)</topic><topic>Pain</topic><topic>Pain - psychology</topic><topic>Prognosis</topic><topic>Quality of Life</topic><topic>Regression Analysis</topic><topic>Sleep</topic><topic>Symptoms</topic><topic>Valine - analogs & derivatives</topic><topic>Valine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mauskopf, Josephine A.</creatorcontrib><creatorcontrib>Austin, Randall</creatorcontrib><creatorcontrib>Dix, Lynn P.</creatorcontrib><creatorcontrib>Berzon, Richard A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Medical care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mauskopf, Josephine A.</au><au>Austin, Randall</au><au>Dix, Lynn P.</au><au>Berzon, Richard A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Estimating the Value of a Generic Quality-of-Life Measure</atitle><jtitle>Medical care</jtitle><addtitle>Med Care</addtitle><date>1995-04-01</date><risdate>1995</risdate><volume>33</volume><issue>4</issue><spage>AS195</spage><epage>AS202</epage><pages>AS195-AS202</pages><issn>0025-7079</issn><abstract>In this paper, data from a clinical trial of a new antiviral agent for treating patients with zoster are used to answer the following question: Does the Nottingham Health Profile (NHP) add to the information obtained from the clinical measures? Three ways in which the NHP could add information are measured. First, Cox's regression analysis is used to determine whether health-related quality-of-life scores obtained at diagnosis give information about disease prognosis. Second, changes in mean NHP scores in different dimensions are computed after pain resolution to determine whether NHP scores provide more sensitive indicators of disease resolution. Third, linear regression is used to determine whether the impacts of disease on quality of life are measured adequately by the clinical parameters. These analyses show that use of the physical mobility and energy dimensions of the NHP increases understanding of disease prognosis; demonstrates the continuing impact of zoster on patients' sleep patterns and energy levels, disease symptoms not included as clinical measures, that persist after the cessation of zoster-associated pain; and gives a measure of the impact of zoster on the patient, which includes unmeasured and measured levels of severity.</abstract><cop>United States</cop><pub>J. B. Lippincott Co</pub><pmid>7723447</pmid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0025-7079 |
ispartof | Medical care, 1995-04, Vol.33 (4), p.AS195-AS202 |
issn | 0025-7079 |
language | eng |
recordid | cdi_proquest_miscellaneous_77223874 |
source | JSTOR Archival Journals and Primary Sources Collection |
subjects | Acyclovir - analogs & derivatives Acyclovir - therapeutic use Antiviral Agents - therapeutic use Central nervous system viral diseases Choosing Questions Clinical trials Demography Diabetes Double-Blind Method Exanthema Female Herpes zoster Herpes Zoster - drug therapy Herpes Zoster - psychology Humans Male Middle Aged Nervous system diseases Outcome Assessment (Health Care) Pain Pain - psychology Prognosis Quality of Life Regression Analysis Sleep Symptoms Valine - analogs & derivatives Valine - therapeutic use |
title | Estimating the Value of a Generic Quality-of-Life Measure |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T02%3A09%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Estimating%20the%20Value%20of%20a%20Generic%20Quality-of-Life%20Measure&rft.jtitle=Medical%20care&rft.au=Mauskopf,%20Josephine%20A.&rft.date=1995-04-01&rft.volume=33&rft.issue=4&rft.spage=AS195&rft.epage=AS202&rft.pages=AS195-AS202&rft.issn=0025-7079&rft_id=info:doi/&rft_dat=%3Cjstor_proqu%3E3766626%3C/jstor_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-j229t-1eee72927fa6549b2395140dd5760163bb45ed3a28e7a9d4a37d5044d7c942eb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=77223874&rft_id=info:pmid/7723447&rft_jstor_id=3766626&rfr_iscdi=true |